*includes studies and abstracts recognized by the American Diabetes Association and International Diabetes Federation.
GlycoMark is FDA-cleared and CE Marked for the intermediate monitoring of glucose control in patients with diabetes. GlycoMark does not reflect hypoglycemia. It does not diagnose any specific diabetes state or disease. The GlycoMark test is FDA-cleared for professional use to provide quantitative measurement of 1,5-Anhydroglucitol (1,5-AG) in serum or plasma. It is not intended to be used to identify patients that will experience complications of diabetes or reduce the likelihood of experiencing complications. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark product insert for more information.